Drug Profile


Alternative Names: CC 122

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Hepatocellular carcinoma
  • Phase I Diffuse large B cell lymphoma; Glioblastoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 17 Apr 2017 Chemical structure information added
  • 30 Mar 2017 Celgene Corporation initiates a phase I pharmacokinetics trial in USA (PO, Capsule) (NCT03097016)
  • 17 Mar 2017 Celgene terminates due to slow enrolment a phase I trial in Hepatocellular carcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable) in USA (PO) (NCT02323906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top